Partnership Coincides with the Grand Opening
of Cryoport's State-Of-The-Art
IntegriCell™ Houston Facility
NASHVILLE, Tenn. and HOUSTON, Oct. 22,
2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:
CYRX) ("Cryoport"), a global leader in supply chain solutions for
the life sciences industry, and Gulf Coast Regional Blood Center
("GCRBC"), a non-profit community blood center serving more than 26
counties throughout the state of Texas, today announced a strategic alliance to
enhance the availability of high-quality, manufacture-ready
cryopreserved allogeneic leukopaks for cellular therapy research,
development, and treatment.
The launch of this partnership coincides with the grand opening
of Cryoport's new state-of-the-art IntegriCell™ facility located at
Cryoport's integrated supply chain campus in Houston, Texas.
This collaboration brings together GCRBC's Cellular Life
Solutions ("CLS") program, which specializes in allogeneic donor
recruitment, management, and apheresis collection, with Cryoport's
industry-leading cryopreservation and biologistics expertise,
creating a comprehensive and unified service offering for the life
sciences community. GCRBC's CLS program is located less than two
miles from Cryoport's Houston
campus, enabling efficient local transport of collected leukopaks
through Cryoport's Cryoshuttle® transportation
service.
"Our partnership with Cryoport allows us to expand the
capabilities of our Cellular Life Solutions program and further
support the critical work being done with cell and gene therapies,"
said Nikhil Nayak, President and CEO
of Gulf Coast Regional Blood Center. "Together, we are creating a
streamlined process that strengthens the quality and consistency of
cellular therapy products, ultimately accelerating the development
of lifesaving treatments for patients."
"By working together with Gulf Coast Regional Blood Center, we
are expanding the reach and impact of our cryopreservation
services," said Jerrell Shelton, CEO
of Cryoport. "This alliance enhances our ability to support the
advancement and commercialization of cell therapies by providing
the infrastructure for seamless, end-to-end delivery of critical
cellular materials. Together, we are helping solve an industry
problem and advance the development of the next generation of
lifesaving cell therapies."
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq:
CYRX), is a global leader in supply chain solutions for the Life
Sciences with an emphasis on cell & gene therapies. Cryoport
enables manufacturers, contract manufacturers (CDMO's), contract
research organizations (CRO's), developers, and researchers to
carry out their respective business with products and services that
are designed to derisk services and provide certainty. We provide a
broad array of supply chain solutions for the life sciences
industry. Through our platform of critical products and solutions
including advanced temperature-controlled packaging, informatics,
specialized bio-logistics services, bio-storage, bio-services, and
cryogenic systems, we are "Enabling the Future of Medicine™"
worldwide, through our innovative systems, compliant procedures,
and agile approach to superior supply chain management.
Our corporate headquarters, located in Nashville, Tennessee, is complemented by over
50 global locations in 17 countries, with key sites in the United States, United Kingdom, France, the
Netherlands, Belgium,
Portugal, Germany, Japan, Australia, India, and China.
For more information, visit www.cryoportinc.com or follow via
LinkedIn at https://www.linkedin.com/company/cryoportinc or
@cryoport on X, formerly known as Twitter at
www.twitter.com/cryoport for live updates.
About Gulf Coast Regional Blood Center
Gulf Coast
Regional Blood Center (GCRBC) is one of the largest community blood
centers in the United States,
serving 170 hospitals and healthcare facilities in a 26-county
area, including the largest medical center in the world, Texas
Medical Center. Founded in 1975, Gulf Coast Regional Blood Center
operates 18 fixed sites and conducts more than 7,000 mobile blood
drives annually to support one of the nation's most diverse cities.
The center also operates Cellular Life Solutions to support the
growing demand for high-quality human cellular starting
material. As an independent, nonprofit organization
accredited by the Food and Drug Administration, our mission is to
partner with the community to help save and sustain lives by
providing a safe supply of blood, biotherapies, and related
services.
For more information, visit www.giveblood.org. Follow via
LinkedIn at
https://www.linkedin.com/company/gulf-coast-regional-blood-center
Forward-Looking Statements
Statements in
this press release which are not purely historical, including
statements regarding Cryoport's intentions, hopes, beliefs,
expectations, representations, projections, plans or predictions of
the future, are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to, those
related to Cryoport's expectations about future benefits of the
support GCRBC's Cellular Life Solutions (CLS) program, including
the potential impact on future revenue and revenue streams.
It is important to note that Cryoport's actual results could differ
materially from those in any such forward-looking statements.
Factors that could cause actual results to differ materially
include, but are not limited to, risks and uncertainties associated
with the effect of changing economic and geopolitical conditions,
supply chain constraints, inflationary pressures, the effects of
foreign currency fluctuations, trends in the products markets,
variations in Cryoport's cash flow, market acceptance risks, and
technical development risks. Cryoport's business could be affected
by other factors discussed in Cryoport's SEC reports, including in
the "Risk Factors" section of its most recently filed periodic
reports on Form 10-K and Form 10-Q, as well as in its subsequent
filings with the SEC. The forward-looking statements contained in
this press release speak only as of the date hereof and Cryoport
cautions investors not to place undue reliance on these
forward-looking statements. Except as required by law, Cryoport
disclaims any obligation, and does not undertake to update or
revise any forward-looking statements in this press
release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cryoport-and-gulf-coast-regional-blood-center-launch-strategic-alliance-to-enhance-cellular-therapy-services-302282921.html
SOURCE Cryoport, Inc.